ClinicalTrials.gg
RecruitingNCT07477561INFINITY-ICOPEUpdated Apr 17, 2026

Optimizing INtrinsic Capacity for Functional INdependence and to Impede FrailTY in Older Adults: Adaptation of the WHO-ICOPE for Healthy Ageing in Singapore

An interventional study of INFINITY-ICOPE programme in Frailty in Older Adults, Intrinsic Capacity and Age-related Functional Decline, sponsored by Sengkang General Hospital. Recruiting at 1 site in Singapore. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Sengkang General Hospital · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Jul 2023, registered Mar 2026).
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
600
Allocation
Non-randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Frailty with a site in Singapore — 12 open to participants now, 13 under way, none of them phase 3. Frailty · Singapore.

Planned enrollment
2nd of 21
600 · median 140
Started
2023
with 1 other
No phase
20 of 28
9 open now
Primary completion
2027-06
later than 10 of 12 live
Registered
26th of 28
by date
Lead sponsor
3 of 28
Sengkang General Hospital

Among the 28 studies in Frailty with a site in Singapore, this one is the 2nd largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2023, is one of 20 with no phase, reaches primary completion later than 10 of the 12 other live ones, and was the 26th registered.

Frailty

1,291 studies on the registry are indexed under Frailty; 454 are open to participants now.

Browse Frailty studies →

Open to participants now

12 of the 28 studies in Frailty with a site in Singapore are open now. Recruiting first, the newest first:

6 more — sign in →

All 12 open studies →

A study can be open while its sites in Singapore have not opened yet or have stopped. Only those recruiting at a site in Singapore →

Who these studies take

Of the 299 Frailty studies recruiting now, 235 (79%) set no upper age limit and 10 (3%) stop at 75 or younger; 7 take children under 18; 66 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Frailty with a site in Singapore, or all of them as a file.
02

Study summary

The goal of this intervention study is to screen and identify frailty and decline in intrinsic capacity (physical and mental capacities) in community-dwelling older adults in Singapore, and to evaluate whether early identification and targeted interventions can improve health outcomes and support healthy ageing. The main questions it aims to answer are:

  • Can combined frailty and intrinsic capacity screening with targeted interventions prevent or reduce functional decline in older adults, as measured by changes in life space mobility?
  • Will at least 80% of screened older adults adhere to recommended care pathways and interventions?
  • Can this screening and intervention programme demonstrate sustainability through continued community participation and recruitment of new partner organizations beyond the initial implementation phase? The investigators will compare an intervention group (receiving immediate assessment and clinical referrals based on identified needs) to a wait-list control group (receiving the same interventions 12 months later) to see if early intervention leads to better health outcomes and quality of life.

Participants will:

  • Attend 4 study visits over 2 years (at 6-monthly intervals in the first year, with final assessment at end of year 2), each lasting up to 2 hours.
  • Undergo comprehensive screening assessments including mobility, cognition, mental health, hearing, vision, and nutritional status.
  • Receive 2 follow-up phone calls at 3-month and 9-month intervals to monitor progress.
  • If in the intervention group: receive personalized referrals for further care (which may include comprehensive geriatric assessment, primary care reviews, rehabilitation, or dietitian consultations) and guidance on using a mobile health monitoring application.
  • If in the wait-list control group: receive the same interventions after their 3rd study visit (12 months later).
Read the detailed description

The INFINITY-ICOPE programme integrates the concepts of frailty and intrinsic capacity - a person's physical and mental abilities essential for maintaining overall health and well-being. Since intrinsic capacity represents the physiological reserves whose decline can lead to frailty, monitoring intrinsic capacity trajectories enables timely intervention to address deteriorating physical and mental capacities. The programmme employs a tiered approach to provide comprehensive geriatric assessment for frail older adults, utilizing technology-enabled tools including the SCREENii algorithmic approach for objective physical frailty assessment and the ENGAGE app to empower older individuals through self-screening, remote intrinsic capacity monitoring, and behavioural nudges.

The investigators primary aim is maintaining older adults' independence and community engagement, measured through life-space mobility. Secondary aims encompass promoting regular screening for frailty and intrinsic capacity decline, implementing early intervention strategies, enhancing quality of life, and developing a cost-effective healthcare delivery model. INFINITY-ICOPE follows the implementation research logic model to ensure rigorous and replicable research. The study comprises 4 phases:

  1. Phase 1 (Proof-of-Concept) - 12 months. This preparatory phase focuses on 3 key areas: technology readiness, care pathway development, and stakeholder readiness assessment.

    • Technology development: The SCREENii platform will be enhanced to provide automated frailty screening through grip strength and gait speed measurements. The ENGAGE app will incorporate WHO-ICOPE Step 1 screening and deliver personalized care plans adapted for local needs.
    • Care pathway development: Personalized pathways will be developed for frailty management through regional hospital networks and intrinsic capacity domain-specific interventions based on WHO-ICOPE guidelines. Community assessors will receive training in Step 1 screening and individualized care planning, with 400 older adults recruited to test feasibility and assess intrinsic capacity decline prevalence.
    • Readiness assessment: Surveys and focus group discussions will evaluate attitudes and expectations of multidisciplinary care providers (eldercare staff, community nurses, family physicians, social workers) towards INFINITY-ICOPE implementation. Additional focus groups with 30 trained community assessors will capture their screening experiences. Usability testing with 15 older adults will assess SCREENii completion times and ENGAGE app quality using the mobile app rating scale. This phase will inform resource planning for Phase 2 and refine implementation strategies based on identified barriers and enablers.
  2. Phase 2 (Proof-of-Value) - 12 months. This single-arm pre-post pilot study will evaluate INFINITY-ICOPE's potential impact by recruiting 60 older adults (aged 60 and above) from an existing mobile frailty screening platform, termed Individual Physical Performance Test for Seniors (IPPT-S). The multi-domain geriatric screening and comprehensive fitness battery will validate SCREENii plus ICOPE Step 1 for stratifying participants by frailty and intrinsic capacity decline.
  3. Phase 3 (Testing-bed) - 30 months. This study employs a pragmatic controlled design with 540 older adults across 8 eldercare and/or active ageing centres within SingHealth zones. Intervention design: The INFINITY-ICOPE programme includes integrated frailty and intrinsic capacity screening, targeted referrals based on stratification, and 6-monthly self-monitoring via ENGAGE app and SCREENii. Participants are stratified into 3 groups post-screening: (a) Frail (regardless of intrinsic capacity status); (b) Non-frail with declining intrinsic capacity; and (c) Non-frail with intact intrinsic capacity.

    Targeted interventions: Frail participants (Fried score of 3 and above) receive comprehensive geriatric assessment at geriatric specialty hubs, whilst non-frail participants with intrinsic capacity decline undergo Steps 2 to 3 assessments at Community Health Posts with personalized interventions. All intervention participants receive ENGAGE app notifications including appointment reminders, lifestyle nudges, and screening prompts. Additional cognitive assessment via Cognify (30-minute automated battery) validated cognitive screening for enhanced stratification. Control group: Continues usual activities with wait-list access to INFINITYICOPE after 12-month outcomes assessment, enabling centres to scale the programme as standard care. Data collection: Comprehensive measures collected at 6-monthly intervals include socio-demographics, frailty / sarcopenia / intrinsic capacity status, medical comorbidities, functional performance, cognitive / mood assessments, quality of life, and intervention adherence, emphasizing both clinical and implementation effectiveness for sustainability evaluation.

  4. Phase 4 (Scale-up) - 6 months. This phase focuses on programme evaluation and scaling preparation without recruiting new participants. Activities centre on completing Phase 3 follow-ups, comprehensive data analysis, and sustainability assessment.
03

Conditions studied

  • Frailty in Older Adults
  • Intrinsic Capacity
  • Age-related Functional Decline
  • Healthy Ageing

Browse trials for

Keywords

  • Frailty
  • Intrinsic capacity decline
  • Community-dwelling older adults
  • Age-related functional decline
  • Healthy ageing
  • Early identification and management of frailty and functional decline
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria: (in Phases 1, 2 and 3):

  • Any Singaporean or Permanent Resident (PR) aged 60 years and above
  • Able to provide (or legally acceptable representative available)

Exclusion Criteria (in Phases 1, 2 and 3):

  • Non-Singaporeans or non-PRs under 60 years of age
  • Residents of sheltered or nursing homes
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
600 participants (estimated)

Study arms

  • Active comparator
    Intervention with further assessment and clinical referrals based on needs identified

    Participants will receive personalized referrals for further care (which may include comprehensive geriatric assessment, primary care reviews, rehabilitation, or dietitian consultations) and guidance on using a mobile health monitoring application.

    Other: INFINITY-ICOPE programme

  • Other
    Wait-listed control

    Participants will continue usual care at active ageing centres and receive the same interventions after their 12-month assessment.

    Other: INFINITY-ICOPE programme

Interventions

  • OtherINFINITY-ICOPE programme

    The INFINITY-ICOPE programme will involve (i) integrated frailty and intrinsic capacity screening, (ii) referral to comprehensive geriatric assessment for frail participants or pathways adapted from the WHO-ICOPE approach for non-frail seniors with intrinsic capacity decline, (iii) 6-monthly self-monitoring for IC and frailty supported through the ENGAGE app and SCREENii.

06

What researchers measure

Primary outcomes

  1. Life space mobility

    To maintain functional independence in older adults, represented by life space mobility (LSM). LSM will be assessed using the University of Alabama Life Space Assessment (LSA) questionnaire. This tool measures the extent of an older adult's movement within their environment, reflecting their community participation and functional independence. The outcome will be expressed as the LSM score, a numerical value derived from the LSA questionnaire, indicating the spatial extent and frequency of movement over the last 4 weeks.

    Time frame: From enrollment to the end of intervention at 12 months.

  2. Community implementation outcomes of INFINITY-ICOPE programme

    Fidelity: Measured by adherence rates (%) to protocol specifications and intervention delivery as intended, assessed through structured fidelity checklists completed by implementation staff. Penetration: Measured as the proportion (%) of eligible older adults reached and enrolled from target community settings, based on programme enrollment records. Sustainability: Measured by the continued operation of the programme and ongoing partner engagement, assessed through documentation of programme activities and partner participation rates (%) beyond the initial implementation period. Follow-up telephone interviews will be conducted at 3 and 9 months post-enrollment to assess participants' self-reported adherence using a standardized questionnaire. Pre- and post-screening surveys with community and primary care providers will evaluate their experience with the INFINITY-ICOPE programme through Likert-scale items, informing programme refinements.

    Time frame: Fidelity: Assessed continuously throughout the 24-month study period. Penetration: Measured at 12 months and 24 months. Sustainability: Evaluated at 24 months and 6 months post-study completion (30 months total).

Secondary outcomes

  1. Adherence to automated frailty screening and remote intrinsic capacity monitoring

    Proportion of participants who complete regular screening assessments using SCREENii technology and engage with remote monitoring through the ENGAGE app, measured by frequency of use, completion rates, and sustained engagement over time.

    Time frame: Assessed at baseline, 6, 12, and 24 months.

  2. Prevention of frailty progression and preservation of intrinsic capacity

    Changes in frailty status and intrinsic capacity status across the 6 domains (mobility, cognition, mental health, hearing, vision, nutrition) following tiered screening and early intervention. Frailty status will be measured using the Fried Frailty Phenotype, reported as the proportion (%) of participants classified as frail, pre-frail, or robust. Intrinsic capacity will be evaluated using the ICOPE Step 1 screening followed by Step 2 clarification assessments for each domain: Mobility: Short Physical Performance Battery (SPPB) score (range 0-12) Cognition: Chinese Mini Mental State Examination (CMMSE) score and a single self-reported memory concern question (presence or absence) Mental health: Geriatric Depression Scale-15 (GDS-15) score Hearing: Screening audiometer results (threshold levels in decibels) Vision: Visual acuity test results using handheld Snellen chart Nutrition: Mini Nutritional Assessment Short Form (MNA-SF) score

    Time frame: Assessed at baseline, 6, 12, and 24 months.

  3. Health-related quality of life improvement

    Changes in validated quality of life measures using EuroQol 5-dimension (EQ-5D-5L) and EuroQol Visual Analogue Scale (EQ-VAS) following INFINITY-ICOPE intervention. For EQ-5D-5L, participants indicate their health by selecting one level in each of five dimensions (mobility, self-care, usual activities, pain / discomfort, anxiety / depression), producing a 5-digit code representing their health state. The EQ-VAS records self-rated health on a 0-100 scale, with endpoints labeled 'best' and 'worst' imaginable health, providing a quantitative measure of perceived health.

    Time frame: Assessed at baseline, 6, 12, and 24 months.

  4. Healthcare service utilization

    Healthcare service utilization will be assessed by the number of emergency department (ED) visits and hospitalizations occurring within the past 6 months or 1 year, depending on the timing of the study visit. The reasons for each ED visit and hospitalization will also be recorded. These measures will be compared between the intervention and control groups.

    Time frame: Assessed at baseline, 6, 12, and 24 months.

  5. Association between oral frailty and physical frailty for risk stratification

    Oral frailty will be assessed using the Oral Frailty Index-8 (OFI-8), which provides a score indicating the degree of oral frailty. The higher the OFI-8 score, the higher the risk of frailty, i.e., 0-2 points indicates low risk; 3 points indicates moderate risk; and greater than 4 points indicates high risk. Physical frailty will be measured using the Fried Frailty Phenotype, categorizing participants as frail, pre-frail, or robust based on established criteria. The outcome will be the correlation between the OFI-8 score and physical frailty status, analyzed to identify relationships that may improve risk stratification and guide targeted interventions within the INFINITY-ICOPE framework.

    Time frame: Assessed at baseline, 6, 12, and 24 months.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — IPD sharing with other researchers is not planned at this time. The research team will evaluate potential data sharing opportunities following study completion, subject to ethical approval, participant consent provisions, and establishment of secure data sharing protocols that maintain participant confidentiality.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2027, 47 months after the start.

Of 514 non-industry interventional studies with no phase under Frailty, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 39. This study's planned 47 months is above that.

Counting every sponsor, half of 519 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2026
First posted
Mar 17, 2026
StartActual
Jul 17, 2023
Primary completionEst.
Jun 30, 2027
CompletionEst.
Jan 15, 2028
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07477561
Lead sponsor
Sengkang General Hospital
Collaborators
Singapore Health Services, Singapore General Hospital, Changi General Hospital, SingHealth Polyclinics, National Dental Centre, Singapore, Geriatric Education and Research Institute, National University of Singapore, Singapore University of Social Sciences
Responsible party
Tay Bee Gek Laura (Senior Consultant, Sengkang General Hospital) — Principal investigator
First posted
Mar 17, 2026
Start date
Jul 17, 2023
Primary completion
Jun 30, 2027 (estimated)
Completion
Jan 15, 2028 (estimated)
Last update
Apr 17, 2026

Study contacts

Denise Qian Ling Chua
Contact
infinity.icope@singhealth.com.sg
6580927146
Laura Bee Gek Tay
principal investigator · Sengkang General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion